Nyxoah S.A. (NYXH)
| Previous close | 8.52 |
| Open | 8.61 |
| Bid | 0.00 x 0 |
| Ask | 8.46 x 200 |
| Day's range | 8.18 - 8.68 |
| 52-week range | 4.00 - 20.00 |
| Volume | |
| Avg. volume | 44,540 |
| Market cap | 250.189M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.66 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.41 |
Globe NewswireInvitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders' meeting of the Company, to be held on Wednesday, June 12, 2024 at 2:00 p.m. CET at the C
- Globe Newswire
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer. Dr. Boon joins Nyxoah from the Thomas Jefferson University, wher
- Globe Newswire
Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), March 29, 2024, 9:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 4,927,355.12 Total number of securities carrying voting rights: 28,682,635 (all ordinary shares) Total number of vo
